Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program

Robert D. Annett, Elizabeth H. Aylward, Jodi Lapidus, Bruce G. Bender, Thomas DuHamel

Research output: Contribution to journalArticle

Abstract

Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.

Original languageEnglish (US)
Pages (from-to)717-724
Number of pages8
JournalThe Journal of Allergy and Clinical Immunology
Volume105
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Asthma
Nebulizers and Vaporizers
Placebos
Lung
Methacholine Chloride
Spirometry
Random Allocation
Intelligence
Social Class
Anti-Inflammatory Agents
Randomized Controlled Trials
Regression Analysis

Keywords

  • Asthma severity
  • Childhood Asthma Management Program
  • Neurocognitive functioning

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program. / Annett, Robert D.; Aylward, Elizabeth H.; Lapidus, Jodi; Bender, Bruce G.; DuHamel, Thomas.

In: The Journal of Allergy and Clinical Immunology, Vol. 105, No. 4, 2000, p. 717-724.

Research output: Contribution to journalArticle

@article{b59d3731f50c492c8e96f105eef8a3bf,
title = "Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program",
abstract = "Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.",
keywords = "Asthma severity, Childhood Asthma Management Program, Neurocognitive functioning",
author = "Annett, {Robert D.} and Aylward, {Elizabeth H.} and Jodi Lapidus and Bender, {Bruce G.} and Thomas DuHamel",
year = "2000",
language = "English (US)",
volume = "105",
pages = "717--724",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program

AU - Annett, Robert D.

AU - Aylward, Elizabeth H.

AU - Lapidus, Jodi

AU - Bender, Bruce G.

AU - DuHamel, Thomas

PY - 2000

Y1 - 2000

N2 - Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.

AB - Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.

KW - Asthma severity

KW - Childhood Asthma Management Program

KW - Neurocognitive functioning

UR - http://www.scopus.com/inward/record.url?scp=0034102279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034102279&partnerID=8YFLogxK

M3 - Article

VL - 105

SP - 717

EP - 724

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -